BioCryst Pharmaceuticals - BCRX Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12-month price targets for BioCryst Pharmaceuticals' shares. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they predict the company's share price to reach $15.78 in the next year. This suggests a possible upside of 83.7% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.

BioCryst Pharmaceuticals' stock was trading at $11.48 at the beginning of the year. Since then, BCRX shares have decreased by 25.2% and is now trading at $8.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our BCRX earnings forecast.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Tuesday, February, 21st. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.19. The biotechnology company had revenue of $79.50 million for the quarter, compared to analysts' expectations of $74.18 million. BioCryst Pharmaceuticals's revenue was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) EPS.

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and First Trust Small Cap Growth AlphaDEX Fund (FYC).

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (2.38%), Geode Capital Management LLC (1.86%), Artisan Partners Limited Partnership (1.54%), Assenagon Asset Management S.A. (1.39%), Victory Capital Management Inc. (1.36%) and Victory Capital Management Inc. (1.34%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCRX stock can currently be purchased for approximately $8.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.62 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

The company employs 358 workers across the globe.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.